DEFA14A: Century Therapeutics Proposes Reverse Stock Split

Century Therapeutics, Inc. will hold a special meeting on January 22, 2026, to vote on a reverse stock split ranging from 1-for-5 to 1-for-30.

Summary

• A special meeting of stockholders for Century Therapeutics, Inc. is scheduled for January 22, 2026, at 9:00 a.m. Eastern Time.
• Stockholders will vote on an amendment to the Company's Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of common stock, par value $0.0001 per share.
• The proposed reverse stock split ratio can be any whole number between 1-for-5 and 1-for-30, with implementation and timing at the Board of Directors' discretion.
• Stockholders will also vote on a proposal to adjourn the Special Meeting if there are insufficient votes to approve the reverse stock split or to establish a quorum.
• The Board of Directors recommends a "FOR" vote on both proposals.
• Proxy materials are available online at www.astproxyportal.com/ast/24419.
• Stockholders can request paper or e-mail copies of proxy materials before January 8, 2026.
• Voting can be done online, virtually at the meeting, by telephone, or by mail.

Sentiment

Score: 3

Explanation: A reverse stock split is generally perceived negatively by the market as it often signals underlying issues with the company's stock performance and can be a precursor to delisting if not successful. While it addresses a compliance issue, it doesn't fundamentally improve the company's business prospects.

Positives

• A reverse stock split could help the company meet minimum bid price requirements for continued listing on a major stock exchange, avoiding potential delisting.
• A higher per-share price might make the stock more attractive to institutional investors and funds that have policies against investing in "penny stocks."
• It could improve the perception of the company's stock value, even if the overall market capitalization remains unchanged.

Negatives

• Reverse stock splits are often perceived negatively by the market, signaling financial distress or a lack of confidence in the company's future performance.
• While the per-share price increases, the overall market capitalization of the company does not change, meaning no fundamental value is added.
• There is no guarantee that a reverse stock split will prevent further stock price declines or improve investor sentiment in the long term.
• It can lead to odd lot holdings for some shareholders, potentially increasing transaction costs.

Risks

• The reverse stock split may not achieve the desired effect of increasing the stock price or maintaining exchange listing requirements over the long term.
• The stock price could continue to decline after the reverse split, potentially leading to another situation where the company faces delisting risks.
• Negative market perception associated with reverse splits could further depress investor confidence and trading volume.

Future Outlook

The filing indicates a strategic move to potentially address stock price and exchange listing requirements, but provides no specific financial or operational guidance for the future.

Management Comments

• The Board of Directors recommends a vote "FOR" Proposals 1 and 2.

Industry Context

Reverse stock splits are common among biotechnology and pharmaceutical companies, particularly those in early development stages or facing clinical setbacks, as a mechanism to maintain compliance with stock exchange listing requirements (e.g., minimum bid price). This action often follows a period of sustained low stock prices.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a reduction in the number of shares held, with a proportional increase in the per-share price. Voting on the proposal is required.
• Investors: May view the reverse split as a negative signal regarding the company's financial health or stock performance, potentially impacting future investment decisions.

Next Steps

• Stockholders to review proxy materials and vote on proposals 1 and 2.
• The Special Meeting of Stockholders will be held on January 22, 2026.
• If approved, the Board of Directors will determine the exact ratio (between 1-for-5 and 1-for-30) and timing of the reverse stock split.

Key Dates

Recommendation

While a reverse stock split is a necessary step for Century Therapeutics to potentially maintain its exchange listing, it does not fundamentally alter the company's business operations or financial health. Investors should hold and monitor for further operational updates and financial performance, as the reverse split itself is a defensive maneuver rather than a growth indicator. The underlying reasons for the low stock price need to be addressed for long-term value creation.

Keywords

Reverse Stock Split, Proxy Statement, Special Meeting, Stockholders, Corporate Governance, Share Price, Delisting Risk, CENTURY THERAPEUTICS, INC.